ES2039276T3 - Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias. - Google Patents

Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.

Info

Publication number
ES2039276T3
ES2039276T3 ES198888300407T ES88300407T ES2039276T3 ES 2039276 T3 ES2039276 T3 ES 2039276T3 ES 198888300407 T ES198888300407 T ES 198888300407T ES 88300407 T ES88300407 T ES 88300407T ES 2039276 T3 ES2039276 T3 ES 2039276T3
Authority
ES
Spain
Prior art keywords
interferon
treatment
combination
preparation
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888300407T
Other languages
English (en)
Inventor
Paul Philip Trotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21712239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2039276(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2039276T3 publication Critical patent/ES2039276T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

CELULAS T Y CELULAA B DE LEUCEMIA HUMANA SON INHIBIDAS DE PROLIFERACION POR TRATAMIENTO CON UNA COMBINACION DE INTERFERONES (ALFA) Y (TAU) HUMANOS RECOMBINANTES, SIMULTANEA O SECUENCIALMENTE, Y EL INTERFERON (ALFA) ES PREFERIBLEMENTE INTERFERON (ALFA)-2B HUMANO RECOMBINANTE.
ES198888300407T 1987-01-20 1988-01-19 Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias. Expired - Lifetime ES2039276T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US473187A 1987-01-20 1987-01-20

Publications (1)

Publication Number Publication Date
ES2039276T3 true ES2039276T3 (es) 1993-09-16

Family

ID=21712239

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888300407T Expired - Lifetime ES2039276T3 (es) 1987-01-20 1988-01-19 Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.

Country Status (7)

Country Link
EP (1) EP0276120B1 (es)
JP (1) JPS63198636A (es)
AT (1) ATE74517T1 (es)
CA (1) CA1321348C (es)
DE (1) DE3869789D1 (es)
ES (1) ES2039276T3 (es)
GR (1) GR3004928T3 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
NZ568135A (en) 2005-10-11 2011-06-30 Array Biopharma Inc Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5562024A (en) * 1978-10-31 1980-05-10 Hayashibara Takeshi Preventive and remedy for interferon-sensitive disease
ZA83768B (en) * 1982-03-01 1983-10-26 Hoffmann La Roche Homogeneous human immune interferon and process therefor
DE3381553D1 (de) * 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
US4806347A (en) * 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
JPS61263929A (ja) * 1986-04-30 1986-11-21 Hayashibara Takeshi 抗タイプ２インターフェロン感受性疾患剤
US4851219A (en) * 1986-11-18 1989-07-25 Genentech, Inc. Method for the treatment of chronic myelogenous leukemia

Also Published As

Publication number Publication date
EP0276120A3 (en) 1989-10-04
GR3004928T3 (es) 1993-04-28
CA1321348C (en) 1993-08-17
EP0276120A2 (en) 1988-07-27
DE3869789D1 (de) 1992-05-14
JPS63198636A (ja) 1988-08-17
ATE74517T1 (de) 1992-04-15
EP0276120B1 (en) 1992-04-08

Similar Documents

Publication Publication Date Title
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
MX9203294A (es) Factor de estimulacion de aniquilador natural.
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
PE72799A1 (es) Interferones polietilen glicol modificados
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
KR910007541A (ko) 백혈병 치료용 제약 조성물
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
ES2039276T3 (es) Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
ATE111357T1 (de) Synergetische immunostimulierende zusammensetzung und ihre verwendung.
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
FI874273A0 (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ATE92333T1 (de) Arzneimittel zur intralesionsbehandlung von schuppenartigem zellkarzinomen mit rekombinantem human-alpha-interferon.
DK527287A (da) Polypeptid med interleukin-2-aktiviteter
ES2011230A4 (es) Derivados peptidos del 3 - aminodihidrotiofeno - 2 - uno, procesos para la preparacion y uso terapeutico
NO882983D0 (no) Oral doseringsform for interferon for menneskelig bruk.
NO871499D0 (no) Stol med leddet boeyelig fjaerryggstoe.
IT8820665A0 (it) Procedimento per la preparazione di (s) e (r) alfa, beta isopropilidenglicerolo.
ATE54941T1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.
ATE98990T1 (de) Menschlicher prourokinase aehnliches polypeptid.
IE882949L (en) Recombinant interleukin-2 formulations
ES1008500Y (es) Mesa desmontable para la practica del tenis de mesa.
DK0381584T3 (da) Anvendelse af visse gamma-interferoner til behandling af ovariecancer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 276120

Country of ref document: ES